Editor’s note: A recording of the conversation is embedded below.
A new type of antibody that can attach to more than one protein target may change the way cancer is treated.
Take a look at some of the entrants in a hot new field with us.
- Irene Ghobrial, M.D., Lavine Family Chair of Preventative Cancer Therapy, professor of medicine, Dana-Farber Cancer Institute
- Jill O’Donnell-Tormey, Ph.D., CEO and director of scientific affairs, Cancer Research Institute
- Damian Garde, national biotech reporter, STAT (moderator)
- Tony Polverino, Ph.D., executive vice president, early development and chief scientific officer, Zymeworks (sponsor speaker)